(Nasdaq: BDSX), a leading diagnostics solutions company, announced the publication of the largest lung nodule biomarker clinical validation study ever conducted. This milestone strengthens the ...
SAN ANTONIO, March 17, 2026--bioAffinity Technologies' new patient case study demonstrates the benefit of CyPath Lung in ...
Imaging studies of more than 27,000 adults link a healthier thymus on CT scans with a longer life and lower risks of ...
Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 ---- Interim systemic lung cancer ...
Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced ...
Cancer cell-derived small extracellular vesicles (sEVs) can travel from distant tumors through the bloodstream and kidneys ...
Imagine you go to the healthcare provider because you have a bad cough, or maybe you fell and hurt your ribs.
Royal Stoke 'missed Mark Shaw's cancer for seven months' ...
Scottish Labour pledge to tackle ‘gross inequalities’ in cancer screening - The pledge comes ahead of the Holyrood elections ...
4don MSN
Long dismissed in adult health, the thymus may be critical for longevity and cancer treatment
Two new studies from investigators at Mass General Brigham challenge a decades-old assumption that the thymus, an organ best known for its role in establishing immune function in childhood, becomes ...
Verastem (VSTM) stock receives a "Buy" rating, driven by progress in KRAS G12D-targeted therapies and multiple 2026 catalysts. Read the full analysis here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results